{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:19Z","timestamp":1793323339341,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1053\/j.ajkd.2020.12.024","type":"journal-article","created":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T11:30:05Z","timestamp":1616671805000},"page":"582-589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"title":["Osteoporosis and Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD): Back to Basics"],"prefix":"10.1053","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-0016","authenticated-orcid":false,"given":"Michael","family":"Pazianas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2020.12.024_bib1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2020.12.024_bib2","unstructured":"Osteoporosis prevention, diagnosis, and therapy. NIH Consens Statement 2000 March 27-29;17(1):1\u201345."},{"issue":"40","key":"10.1053\/j.ajkd.2020.12.024_bib3","doi-asserted-by":"crossref","first-page":"27438","DOI":"10.1074\/jbc.M109.023572","article-title":"Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton","volume":"284","author":"Almeida","year":"2009","journal-title":"J\u00a0Biol Chem"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11914-019-00498-x","article-title":"Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments","volume":"17","author":"Lane","year":"2019","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib5","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00198-017-4228-4","article-title":"Two-year cortical and trabecular bone loss in CKD-5D: biochemical and clinical predictors","volume":"29","author":"Malluche","year":"2018","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1053\/j.ajkd.2020.12.024_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S2213-8587(17)30184-5","article-title":"Use of bone turnover markers in postmenopausal osteoporosis","volume":"5","author":"Eastell","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1053\/j.ajkd.2020.12.024_bib7","first-page":"366","volume":"58","author":"Lange","year":"1974","journal-title":"Verh Dtsch Ges Pathol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1159\/000486907","article-title":"Tick-tock chimes the kidney clock\u2014from biology of renal ageing to clinical applications","volume":"43","author":"Rowland","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1053\/j.ajkd.2020.12.024_bib9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1681\/ASN.2016020154","article-title":"The substantial loss of nephrons in healthy human kidneys with aging","volume":"28","author":"Denic","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.024_bib10","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/j.1523-1755.2005.00365.x","article-title":"Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"67","author":"Levey","year":"2005","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2020.12.024_bib11","first-page":"1","article-title":"Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group","volume":"843","year":"1994","journal-title":"World Heath Organ Tech Rep Ser"},{"key":"10.1053\/j.ajkd.2020.12.024_bib12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s11914-017-0364-1","article-title":"Renal osteodystrophy or kidney-induced osteoporosis?","volume":"15","author":"Moe","year":"2017","journal-title":"Curr Osteoporos Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.024_bib13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jbm4.10117","article-title":"Rethinking bone disease in kidney disease","volume":"2","author":"Damasiewicz","year":"2018","journal-title":"JBMR Plus"},{"key":"10.1053\/j.ajkd.2020.12.024_bib14","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"632","article-title":"Pathophysiology of chronic kidney disease mineral bone disorder (CKD-MBD)","author":"Hruska","year":"2013"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.024_bib15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s11914-018-0483-3","article-title":"Gonadal hormones in the pathogenesis and treatment of bone health in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Aleksova","year":"2018","journal-title":"Curr Osteoporos Rep"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jocd.2012.11.013","article-title":"Skeletal effects of primary hyperparathyroidism: bone mineral density and fracture risk","volume":"16","author":"Lewiecki","year":"2013","journal-title":"J\u00a0Clin Densitom"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.024_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jocd.2017.06.022","article-title":"FRAX update","volume":"20","author":"Kanis","year":"2017","journal-title":"J\u00a0Clin Densitom"},{"issue":"8","key":"10.1053\/j.ajkd.2020.12.024_bib19","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/jbmr.4134","article-title":"Defining very high fracture risk: is FRAX fit for purpose?","volume":"35","author":"Compston","year":"2020","journal-title":"J\u00a0Bone Miner Res"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.024_bib21","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/ndt\/gfz198","article-title":"How and when to assess\u00a0bone mineral density and bone quality in chronic kidney disease patients?","volume":"36","author":"Khairallah","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2020.12.024_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.024_bib23","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00198-018-4468-y","article-title":"The trabecular bone score is associated with bone mineral density, markers of bone turnover and prevalent fracture in patients with end stage kidney disease","volume":"29","author":"Aleksova","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1053\/j.ajkd.2020.12.024_bib24","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00198-020-05458-1","article-title":"Trabecular bone score in patients with chronic kidney disease","volume":"31","author":"Rampersad","year":"2020","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.024_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ki.2012.166","article-title":"Bone microarchitecture is more severely affected in patients on hemodialysis than in those receiving peritoneal dialysis","volume":"82","author":"Pelletier","year":"2012","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2020.12.024_bib26","unstructured":"New tools to predict fracture risk. Mayo Clinic. November 25, 2015. Accessed March 31, 2021. https:\/\/www.mayoclinic.org\/medical-professionals\/endocrinology\/news\/new-tools-to-predict-fracture-risk\/mac-20430573"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2020.12.024_bib27","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2215\/CJN.02430508","article-title":"The role of bone biopsy in patients with chronic renal failure","volume":"3","author":"Miller","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1053\/j.ajkd.2020.12.024_bib28","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3949\/ccjm.76a.08108","article-title":"Fragility fractures in chronic kidney disease: an opinion-based approach","volume":"76","author":"Miller","year":"2009","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.024_bib29","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1681\/ASN.2018030289","article-title":"The quest for better biomarkers of bone turnover in CKD","volume":"29","author":"Nickolas","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2020.12.024_bib30","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2020.12.024_bib31","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1681\/ASN.2015020117","article-title":"Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD","volume":"26","author":"Isakova","year":"2015","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2020.12.024_bib32","first-page":"CD006023","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"8","author":"Ruospo","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.024_bib33","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2215\/CJN.11031017","article-title":"Management of osteoporosis in CKD","volume":"13","author":"Khairallah","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"13(suppl 1)","key":"10.1053\/j.ajkd.2020.12.024_bib34","doi-asserted-by":"crossref","first-page":"39","DOI":"10.5414\/CNP88FX10","article-title":"Bone mineral disturbances in patients with chronic kidney disease stage 5 not yet on dialysis","volume":"88","author":"Marn Pernat","year":"2017","journal-title":"Clin Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2020.12.024_bib35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/17446651.2017.1347501","article-title":"Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease","volume":"12","author":"Sprague","year":"2017","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib36","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/s41598-018-20552-5","article-title":"Cinacalcet use and the risk of cardiovascular events, fractures and mortality in chronic kidney disease patients with secondary hyperparathyroidism","volume":"8","author":"Evans","year":"2018","journal-title":"Sci Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.024_bib37","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/j.ajkd.2015.01.025","article-title":"Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report","volume":"65","author":"Palcu","year":"2015","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2020.12.024_bib38","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"issue":"10","key":"10.1053\/j.ajkd.2020.12.024_bib39","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/jbmr.149","article-title":"Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies","volume":"25","author":"Reid","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1053\/j.ajkd.2020.12.024_bib40","first-page":"325","article-title":"Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis","volume":"6","author":"Pazianas","year":"2010","journal-title":"Ther Clin Risk Manag"},{"issue":"10","key":"10.1053\/j.ajkd.2020.12.024_bib41","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1002\/jbmr.2058","article-title":"Renal safety in patients treated with bisphosphonates for osteoporosis: a review","volume":"28","author":"Miller","year":"2013","journal-title":"J\u00a0Bone Miner Res"},{"issue":"2","key":"10.1053\/j.ajkd.2020.12.024_bib42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000380960","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib43","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1053\/j.ajkd.2020.12.024_bib44","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00198-010-1226-1","article-title":"Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis","volume":"22","author":"Macdonald","year":"2011","journal-title":"Osteoporos Int"},{"issue":"4","key":"10.1053\/j.ajkd.2020.12.024_bib45","doi-asserted-by":"crossref","first-page":"392-400","DOI":"10.1007\/s00223-019-00642-w","article-title":"Elevations in cortical porosity occur prior to significant rise in serum parathyroid hormone in young female mice with adenine-induced CKD","volume":"106","author":"Metzger","year":"2020","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.1053\/j.ajkd.2020.12.024_bib46","doi-asserted-by":"crossref","first-page":"376-384","DOI":"10.1159\/000489671","article-title":"Deterioration of cortical bone microarchitecture: critical component of renal osteodystrophy evaluation","volume":"47","author":"Sharma","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2020.12.024_bib47","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1053\/j.ajkd.2020.12.024_bib48","unstructured":"Eli Lilly and Company. \u201cOsteosarcoma Boxed Warning, Removed Nov 2020,\u201d FORTEO (teriparatide injection), for subcutaneous use, Initial U.S. Approval: 1987. Lilly USA; 2020. Accessed March 31, 2021. https:\/\/pi.lilly.com\/us\/forteo-pi.pdf"},{"issue":"12","key":"10.1053\/j.ajkd.2020.12.024_bib49","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/jbmr.4155","article-title":"The CKD-MBD syndrome: hysteresis in PTH involvement and PTH administration for its management","volume":"35","author":"Pazianas","year":"2020","journal-title":"J Bone Miner Res"},{"key":"10.1053\/j.ajkd.2020.12.024_bib50","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/ki.1976.42","article-title":"Bone histology in incipient and advanced renal failure","volume":"9","author":"Malluche","year":"1976","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2020.12.024_bib51","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ndt\/6.3.162","article-title":"Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism","volume":"6","author":"Reichel","year":"1991","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2020.12.024_bib52","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2020.12.024_bib53","first-page":"1","article-title":"Current understanding of mineral and bone disorders of chronic kidney disease and the scientific grounds on the use of exogenous parathyroid hormone in its management","volume":"27","author":"Pazianas","year":"2020","journal-title":"J\u00a0Bone Metab"},{"issue":"11","key":"10.1053\/j.ajkd.2020.12.024_bib54","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1210\/endo.138.11.5505","article-title":"The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats","volume":"138","author":"Dobnig","year":"1997","journal-title":"Endocrinology"},{"key":"10.1053\/j.ajkd.2020.12.024_bib55","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00198-016-3861-7","article-title":"Efficacy and safety of osteoporosis medications in a rat model of late-stage chronic kidney disease accompanied by secondary hyperparathyroidism and hyperphosphatemia","volume":"28","author":"Ota","year":"2017","journal-title":"Osteoporos Int"},{"issue":"1128","key":"10.1053\/j.ajkd.2020.12.024_bib56","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1136\/postgradmedj-2019-136699","article-title":"Bones, heart and the new anabolic agent romosozumab","volume":"95","author":"Pazianas","year":"2019","journal-title":"Postgrad Med J"},{"issue":"3","key":"10.1053\/j.ajkd.2020.12.024_bib57","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ndt\/gfy129","article-title":"Sclerostin in chronic kidney disease-mineral bone disorder think first before you block it!","volume":"34","author":"Brandenburg","year":"2019","journal-title":"Nephrol Dial Transplant"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862100500X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027263862100500X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:41:11Z","timestamp":1759462871000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027263862100500X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S027263862100500X"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.024","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoporosis and Chronic Kidney Disease\u2013Mineral and Bone Disorder (CKD-MBD): Back to Basics","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2020.12.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}